Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-milligram versus 1-milligram acenocoumarol dosing in patients aged 80 years and older
NL-OMON45279Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acenocoumarol in Atrial fibrillation (AFib), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Quality of anticoagulation, Individual time in therapeutic range and 1 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
acenocoumarol
03
Conditions
Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON45279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45279.